Invizius

United Kingdom - Motherwell, North Lanarkshire

• 24/09/2024
• Unknown
• $1,270,710

Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland. Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with Acute Kidney Injury receiving CRRT and patient on Renal replacement Therapy receiving Peritoneal Dialysis.

Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Complement activation has also been associated with Peritoneal Dialysis(PD) and may be a driver of fibrotic changes that limit PD duration.

Related People

Dr Magnus Nicolson MBA FRSM FRSCFounder

United Kingdom - Balfron, Scotland

I have been Chairman, CEO and Managing Director of public and private life science companies in the US, UK, Sweden, Germany and the Gulf States. My passion is building exceptional teams that efficiently make or deliver life changing products and services.

Experience & Skills: Leadership, Project Management, Venture Funding, IPO's, Start Ups & Scale Ups, Partnering & Licensing, cGMP Manufacture, Drug Delivery, API's, Biopharmaceuticals, RNA therapeutics, Cell and Gene Therapies, Exosomes, Immunodiagnostics, Marine Biotechnology, Omega 3's, Chemical & Process Engineering.

LinkedIn https://www.linkedin.com/in/lifescienceceo/